Gene test may spare melanoma patients unnecessary surgery

NCT ID NCT04759781

Ongoing Knowledge-focused Sponsor: SkylineDx Source: ClinicalTrials.gov ↗

First seen Apr 29, 2026 · Last updated May 04, 2026 · Updated 1 time

Summary

This study is testing a new gene test (Merlin Assay) on tumor samples from 1,820 people with newly diagnosed melanoma. The goal is to see if the test can accurately predict whether the cancer has spread to nearby lymph nodes, which could help some patients avoid an invasive biopsy. Researchers will also track patients for 3-5 years to see if the test predicts cancer recurrence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Duke University

Durham, North Carolina, 27705, United States
Emory University School of Medicine

Atlanta, Georgia, 30322, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
University of Kentucky

Lexington, Kentucky, 40506, United States
University of Louisville

Louisville, Kentucky, 40292, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.

MELANOMA